Johns Hopkins and local biotech team up for new manufacturing site; New oral drug platform to help accelerate R&D timeline
Johns Hopkins University and a Maryland-based biotech will join forces to develop a cell and gene therapy processing facility at the university, set to open in 2023.
Orgenesis will join forces on the POCare Center, also known as the Maryland Center for Cell Therapy Manufacturing, in part thanks to a $5 million grant from the state. The facility will be 7,000 square feet, and help clinicians and researchers at Johns Hopkins with a more streamlined path from the lab to patient trials. This allows for more in-house manufacturing, and less outsourcing to third parties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.